Triterpene and Steroids from Ludwigia abyssinica A. Rich (Onagraceae) Displayed Antimicrobial Activities and Synergistic Effects with Conventional Antibiotics

Abstract

Difficulties encountered in treating drug-resistant pathogens have created a need for new therapies. Synergistic combinations of antibiotics are considered as ideal strategies in combating clinical and multidrug-resistant (MDR) infections. In this study, the antimicrobial activities of triterpenes and steroids from Ludwigia abyssinica A. Rich (Onagraceae) and their combined effects with antibiotics were assessed. The associations between plant constituents and antibiotics were evaluated by determining their fractional inhibitory concentrations (FICs). Sitost-5-en-3β-ol formiate (1), 5α,6β-dihydroxysitosterol (2), and maslinic acid (3) were isolated from the L. abyssinica ethyl acetate (EtOAc) extract. The EtOAc extract, compounds 1, 2, and 3 (MIC = 16–128 µg/mL) would be the best antibacterial and antifungal agents. The antimicrobial activities of amoxicillin were relatively weak against MDR Escherichia coli and Shigella flexneri and significant against Staphylococcus aureus ATCC 25923. However, when used in association with plant constituents, it displayed an interesting synergistic effect. Among plant components-antibiotic combinations, the EtOAc extract and compound 1 (steroid) showed a synergistic effect with amoxicillin/fluconazole against all the tested microorganisms whereas the association of compound 3 (triterpenoid) and amoxicillin/fluconazole displayed an additive effect against Shigella flexneri and Escherichia coli and a synergistic effect on Staphylococcus aureus, Cryptococcus neoformans, Candida tropicalis, and Candida albicans ATCC 10231. Overall, the results of the present study demonstrated antibacterial and antifungal activities of extracts and compounds isolated from L. abyssinica. The findings of the current study also showed that the potency of antibiotics was improved when screened in combination with L. abyssinica components, supporting the drug combination strategy to combat antimicrobial resistance.